8-K: Biodesix Faces Nasdaq Delisting Threat Due to Low Stock Price

Biodesix, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.

Summary

• Biodesix, Inc. received a notification from Nasdaq on March 24, 2025, stating that its common stock has not met the minimum bid price of $1.00 per share for 30 consecutive business days.
• This violates Nasdaq Listing Rule 5450(a)(1).
• Biodesix has an initial period until September 22, 2025, to regain compliance.
• Compliance can be achieved if the stock price closes at or above $1.00 for at least ten consecutive business days.
• If compliance is not met, Biodesix may be eligible for an additional 180-day compliance period if it meets other listing requirements.
• If the company fails to regain compliance and is ineligible for an extension, Nasdaq will issue a delisting notification, which the company can appeal.
• Biodesix intends to monitor its stock price and is considering options, including a reverse stock split, to regain compliance.
• There is no guarantee that a reverse stock split will occur or be effective.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and uncertainty surrounding the company's ability to regain compliance. The consideration of a reverse stock split suggests underlying financial concerns.

Negatives

• Biodesix's stock price has fallen below the required $1.00 minimum for continued listing on the Nasdaq Global Market.
• The company faces potential delisting if it cannot regain compliance by September 22, 2025.
• There is no guarantee that a reverse stock split, if implemented, will be successful in raising the stock price.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement could result in delisting.
• A reverse stock split may not be effective in increasing the stock price.
• The company's stock price may continue to decline, making compliance more difficult.

Future Outlook

The company intends to monitor the closing bid price of its common stock and will consider various options available to it if its common stock does not trade at a level to regain compliance with the Minimum Bid Price Requirement, including effecting a reverse stock split.

Management Comments

• The Company intends to monitor the closing bid price of its common stock and will consider various options available to it if its common stock does not trade at a level to regain compliance with the Minimum Bid Price Requirement.

Industry Context

Delisting notices are not uncommon, especially for smaller biotech companies facing financial or operational challenges; many companies in similar situations explore options like reverse stock splits or attempt to improve their financial performance to regain compliance.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining Nasdaq listing requirements.
• Reverse stock splits are a common strategy employed by companies in this situation, although their success rate varies.
• Companies like Geron Corporation and Ocugen Inc. have previously faced similar delisting warnings and implemented reverse stock splits to regain compliance.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security.
• The company's reputation and ability to attract future investment may be negatively impacted.

Next Steps

• Biodesix will monitor its stock price.
• Biodesix will consider options to regain compliance, including a reverse stock split.
• Biodesix may appeal a delisting determination if it occurs.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, reverse stock split, Biodesix, stock price